A First Human Study of a Ferroportin Antibody
Condition: Healthy Volunteers
Intervention: Placebo; LY2928057
Intervention description: Single intravenous placebo dose.; Single intravenous dose.
Phase: Phase 1
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 32.0
Sex: All
Minimum age: 21 Years
Maximum age: 60 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Anemia

Summary:

      The purposes of this study are to evaluate the following in healthy participants: 1)
      LY2928057 safety, including any side effects possibly associated with LY2928057; 2) how the
      body processes LY2928057; 3) effect of LY2928057 on blood iron levels; and 4) immune system
      reactions to LY2928057.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Must either be a healthy male (and willing to use reliable birth control method during
             the study and for 3 months following last study drug dose), or a healthy female who
             cannot become pregnant

          -  Must have a body mass index (BMI) between 18.5 and 32.0 kilograms per square meter
             (kg/m^2), inclusive, and a minimum body weight of 55 kg

          -  Must have acceptable blood and urine laboratory test results for the study

          -  Must have suitable veins suitable for easy blood collection and study drug
             administration

          -  Must be reliable, follow study procedures, and willing to be available for the
             duration of the study

          -  Must have given written informed consent

          -  Must have acceptable blood pressure and pulse rate for the study

        Exclusion Criteria:

          -  Blood test shows that participant has anemia due to lack of iron

          -  Currently participating in another clinical study or has completed one less than 30
             days ago

          -  Allergic to biologic agents

          -  Have previously taken part in this study

          -  Have abnormal electrocardiogram (ECG) findings that suggest an increased risk with
             study participation

          -  Have a history of significant disease that may affect drug actions or pose risk when
             taking study medication

          -  Have a history of drug or alcohol abuse

          -  Are infected with human immunodeficiency virus (HIV)

          -  Have hepatitis B

          -  Are pregnant or breastfeeding

          -  Intend to use over-the-counter or prescription medication within 14 days before
             dosing, other than oestrogen/progesterone as hormone replacement therapy (HRT).
             Participants taking these medications are expected to be on chronic, stable doses.
             Certain medications (for example, vitamin supplements) may be permitted at the
             discretion of the investigator.

          -  Have donated more than 450 milliliter (mL) of blood within the last 3 months

          -  Have a regular alcohol intake greater than 21 units per week (male), or 14 units per
             week (female), or are unwilling to stop alcohol as required for the study (1 unit =
             360 mL of beer, 150 mL of wine, or 45 mL of spirits)

          -  Are a smoker (smoking more than 10 cigarettes per day) or have used equivalent tobacco
             products. Participants will not be allowed to smoke while in the study unit.

          -  Have received live vaccine(s) within 1 month of screening, or intend to during the
             study

          -  Have received treatment with biologic agents (such as monoclonal antibodies) within 3
             months or 5 half-lives (whichever is longer) before receiving study drug in this study

          -  Have a history of atopy, significant allergies to humanized monoclonal antibodies,
             clinically significant multiple or severe drug allergies, intolerance to topical
             corticosteroids, or severe post-treatment hypersensitivity reactions (including, but
             not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis,
             toxic epidermal necrolysis, and exfoliative dermatitis)

          -  Have any active mental health illness

          -  Study doctor does not feel the participant should be in the study for any reason